Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8085847 | 1.00 | HTT (0.42) | HTTHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8091030 | 0.86 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL13078590 | 0.86 | HTT (0.38) | HTTHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6882378 | 0.86 | HTT (0.38) | HTTHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3747970 | 0.85 | HTR2C (0.43) | HTTHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13045367 | 0.85 | HTR2C (0.43) | HTTHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8090235 | 0.83 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL13078569 | 0.83 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3738672 | 0.82 | CTRB1 (0.46) | HTR2CNPC1RAB9ASMN1; SMN2AGTR2 | |
| SCHEMBL8079814 | 0.82 | HTT (0.46) | HTTHTR2CNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | HTT 3456/4885HTR2C 2412/4885NPC1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.